rs150362958

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BS1BS2

The NM_001256715.2(DNAAF3):​c.6C>T​(p.Thr2Thr) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0118 in 1,613,794 control chromosomes in the GnomAD database, including 131 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0082 ( 13 hom., cov: 32)
Exomes 𝑓: 0.012 ( 118 hom. )

Consequence

DNAAF3
NM_001256715.2 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:8

Conservation

PhyloP100: 0.661

Publications

2 publications found
Variant links:
Genes affected
DNAAF3 (HGNC:30492): (dynein axonemal assembly factor 3) The protein encoded by this gene is required for the assembly of axonemal inner and outer dynein arms and plays a role in assembling dynein complexes for transport into cilia. Defects in this gene are a cause of primary ciliary dyskinesia type 2 (CILD2). Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]
DNAAF3-AS1 (HGNC:55292): (DNAAF3 antisense RNA 1)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.43).
BP6
Variant 19-55166408-G-A is Benign according to our data. Variant chr19-55166408-G-A is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 238684.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.661 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.00817 (1244/152248) while in subpopulation NFE AF = 0.0145 (985/68020). AF 95% confidence interval is 0.0137. There are 13 homozygotes in GnomAd4. There are 561 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 13 AR,AD gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
DNAAF3NM_001256715.2 linkc.6C>T p.Thr2Thr synonymous_variant Exon 2 of 12 ENST00000524407.7 NP_001243644.1 Q8N9W5-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
DNAAF3ENST00000524407.7 linkc.6C>T p.Thr2Thr synonymous_variant Exon 2 of 12 1 NM_001256715.2 ENSP00000432046.3 Q8N9W5-1

Frequencies

GnomAD3 genomes
AF:
0.00818
AC:
1244
AN:
152130
Hom.:
13
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00234
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00465
Gnomad ASJ
AF:
0.00144
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00290
Gnomad FIN
AF:
0.00565
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.0145
Gnomad OTH
AF:
0.00478
GnomAD2 exomes
AF:
0.00789
AC:
1959
AN:
248134
AF XY:
0.00786
show subpopulations
Gnomad AFR exome
AF:
0.00194
Gnomad AMR exome
AF:
0.00321
Gnomad ASJ exome
AF:
0.00209
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00748
Gnomad NFE exome
AF:
0.0131
Gnomad OTH exome
AF:
0.00893
GnomAD4 exome
AF:
0.0122
AC:
17818
AN:
1461546
Hom.:
118
Cov.:
33
AF XY:
0.0120
AC XY:
8733
AN XY:
727052
show subpopulations
African (AFR)
AF:
0.00182
AC:
61
AN:
33480
American (AMR)
AF:
0.00367
AC:
164
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00241
AC:
63
AN:
26136
East Asian (EAS)
AF:
0.0000252
AC:
1
AN:
39700
South Asian (SAS)
AF:
0.00406
AC:
350
AN:
86252
European-Finnish (FIN)
AF:
0.00839
AC:
447
AN:
53246
Middle Eastern (MID)
AF:
0.00260
AC:
15
AN:
5768
European-Non Finnish (NFE)
AF:
0.0146
AC:
16185
AN:
1111862
Other (OTH)
AF:
0.00881
AC:
532
AN:
60378
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.478
Heterozygous variant carriers
0
1161
2322
3484
4645
5806
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
596
1192
1788
2384
2980
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00817
AC:
1244
AN:
152248
Hom.:
13
Cov.:
32
AF XY:
0.00754
AC XY:
561
AN XY:
74442
show subpopulations
African (AFR)
AF:
0.00233
AC:
97
AN:
41544
American (AMR)
AF:
0.00464
AC:
71
AN:
15298
Ashkenazi Jewish (ASJ)
AF:
0.00144
AC:
5
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5168
South Asian (SAS)
AF:
0.00291
AC:
14
AN:
4816
European-Finnish (FIN)
AF:
0.00565
AC:
60
AN:
10614
Middle Eastern (MID)
AF:
0.00680
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
0.0145
AC:
985
AN:
68020
Other (OTH)
AF:
0.00473
AC:
10
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
69
138
207
276
345
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0104
Hom.:
8
Bravo
AF:
0.00784
Asia WGS
AF:
0.00260
AC:
9
AN:
3478
EpiCase
AF:
0.0110
EpiControl
AF:
0.0119

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Feb 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

DNAAF3: BP4, BP7, BS1, BS2 -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Jul 28, 2020
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:2
Mar 28, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Primary ciliary dyskinesia Benign:2
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 18, 2019
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Primary ciliary dyskinesia 2 Benign:1
Nov 30, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.43
CADD
Benign
13
DANN
Benign
0.93
PhyloP100
0.66
PromoterAI
0.014
Neutral
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs150362958; hg19: chr19-55677776; API